Beta Bionics, Inc. (BBNX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-1006.1%

-$144.06

vs $15.90 price

Levered DCF

-$181.04

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

9.08

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-16.83×	-18.46×	-22.94×	-15.65×
P/B	4.29×	13.32×	17.28×	-5.96×
P/S	12.32×	15.55×	84.43×	5,657.91×
EV / EBITDA	-17.22×	-18.86×	-23.58×	-15.79×
Gross margin	55.4%	55.1%	52.6%	100.0%
Operating margin	-71.5%	-69.5%	-298.9%	-36784.4%
Net margin	-73.0%	-84.1%	-367.6%	-36173.7%
Current ratio	8.66×	6.29×	9.77×	3.21×
Debt / equity	0.03×	0.1×	0.07×	-0.02×
Interest coverage	0×	0×	0×	-4,703.14×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-25.5%	-72.0%	-75.2%	38.1%
Return on invested capital	-23.9%	-34.8%	-35.6%	-238.3%
Return on assets	-22.3%	-36.6%	-40.1%	-182.3%
Free cash flow yield	-4.6%	-5.1%	-3.2%	-6.0%
Earnings yield	-5.9%	-5.4%	-4.4%	-6.4%
Enterprise value	$1.2B	$989.6M	$990.4M	$989.2M
Net debt / EBITDA	0.35×	0.44×	0.53×	0.38×
Cash conversion cycle (days)	209	198	140	0